摘要
呼吸道合胞病毒(RSV)是全球婴幼儿呼吸道疾病的主要病原,且小婴儿感染出现严重疾病的发生率最高,急需有效预防措施预防RSV感染。目前,尚无疫苗获批用于预防RSV感染。2021年6月世界卫生组织(WHO)制定了《世界卫生组织推荐用于呼吸道合胞病毒感染被动免疫理想的单克隆抗体的产品特性》。文件旨在促进开发高质量、安全、可负担和有效的单克隆抗体,预防全球婴幼儿严重RSV疾病和与RSV相关死亡。现就该文件进行解读,以帮助广大儿科医师了解RSV感染被动免疫的单克隆抗体的产品理想特性和应用前景。
Respiratory syncytial virus(RSV)is the main pathogen of respiratory diseases in infants and young children worldwide,and the incidence of severe RSV infection remains highest in infants.Effective preventive measures are urgently needed to prevent RSV infection.Currently,no vaccine has been approved to prevent RSV infection.In June 2021,World Health Organization(WHO)proposed the Characteristics of Monoclonal Antibodies for Passive Immunization against Respiratory Syncytial Virus Infection which facilitates the development of high-quality,safe,affordable and effective monoclonal antibodies to prevent severe RSV infection and deaths in infants and young children worldwide.This study aims to interpret this document,thus guiding pediatricians understand the ideal characteristics and application of monoclonal antibodies for passive immunity to RSV infection.
作者
卢根
申昆玲
Lu Gen;Shen Kunling(Department of Respiratory Medicine,Guangzhou Women and Children′s Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Respiratory Medicine,Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,National Clinical Research Center for Respiratory Diseases,Beijing 100045,China)
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2021年第24期1844-1847,共4页
Chinese Journal of Applied Clinical Pediatrics
关键词
预防
被动免疫
呼吸道合胞病毒
单克隆抗体
Prevention
Passive immunity
Respiratory syncytial virus
Monoclonal antibody
